PP140 Economic Evaluation Of Several Vaccination Strategies Against Rotavirus In Spain

Introduction The Spanish Ministry of Health asked us about the efficiency extending current rotavirus vaccination strategy to all newborns. is vaccinate only high-risk newborns (premature and those qualified as by a pediatrician). objective this research was compare three strategies: no-vaccination, universal vaccination, considering two vaccines available in Spain: RotaTeq® Rotarix®. Methods A cost-utility analysis, based on de novo Markov model, carried out both from societal healthcare system perspective. model follows cohort during their life-course. cycle length annual half-cycle correction applied. discount rate 3 percent applied base case costs utilities. Most incidence, probabilities data were Spanish. Quality Adjusted Life Year (QALY) taken international literature. We assumed willingness pay threshold EUR 25,000 per QALY gained. performed deterministic one-way sensitivity analysis. Results Compared cost-effective assuming above- mentioned with Rotarix® perspective (RotaTeq® 32,008 QALY; 23,368 QALY). Universal not either compared no-vaccination or perspectives. Vaccine prices efficacy are highly sensitive variables. find that would be 44.6 36.9 price Rotarix®, respectively. Conclusions for Spain at prices. Vaccination Substantial reductions could make option Spain.